Sign up

Sign up

Administration designed with you in mind

Needles provided separately and may require a prescription in some states. A new needle is required for each injection.

We’ll cover important information you should be aware of

  • Alhemo® is given as an injection under the skin (subcutaneous injection) once daily by you or a caregiver.

  • Use Alhemo® exactly as prescribed by your healthcare provider.

  • Read the Instructions for Use for information about how to prepare and inject Alhemo®, and how to properly throw away used pens and needles.

  • Your healthcare provider should show you or your caregiver how to use Alhemo® before you use it for the first time.

Needles provided separately and may require a prescription in some states. A new needle is required for each injection.

Starting Alhemo®

What your first few days and weeks could look like.

After four weeks

Prepare and learn more about the laboratory test.

Daily administration

Learn how to use the Alhemo® pen.

The pens

3 sizes to meet your dosing needs.

Laboratory test

Check Alhemo® levels in your blood and get individualized dosing.

Admin comparison

Lorem ipsum description

What to know about personalized dosing

Alhemo® has a test that measures the amount of concizumab-mtci in your blood. This allows your healthcare provider to prescribe the dose that fits your body's needs.

Day 1

  • You will inject a larger dose (a loading dose) of Alhemo® on your first day of treatment

  • Your dose will be based on your weight: 1 mg/kg

Day 2+

  • Your dose will now be 0.2 mg/kg 1 time per day until you take a blood test

Day 28

(4 weeks after starting Alhemo®)

  • To determine the right maintenance dose, you will take the blood test, which will show how much Alhemo® is in your bodya

  • Your healthcare provider may do additional blood tests during treatment with Alhemo®

aShould be performed before administering next scheduled dose.

 Stopwatch icon

Prepare for your laboratory test

  • Schedule your blood draw appointment and confirm its location—which may not be at your doctor’s office.
  • Wait until after the blood draw to take your daily dose of Alhemo® on the day of your test.

It is important to follow the daily dosing schedule of Alhemo® to stay protected against bleeding, especially during the first 4 weeks of treatment, to help establish your maintenance dose.

It is important to follow the daily dosing schedule of Alhemo® to stay protected against bleeding, especially during the first 4 weeks of treatment, to help establish your maintenance dose.

If you miss a dose during the first 4 weeks of treatment, contact your healthcare provider right away. Your healthcare provider will tell you how much Alhemo® to inject.

If you miss a dose during the first 4 weeks of treatment, contact your healthcare provider right away. Your healthcare provider will tell you how much Alhemo® to inject.

If you miss doses, or stop using Alhemo®, you may no longer be protected against bleeding.

Administration designed with you in mind

Alhemo® is given as an injection under the skin (subcutaneous injection) by you or a caregiver.

Alhemo® is administered once daily.

Needles provided separately and may require a prescription in some states; a new needle is required for each injection.

Read the Instructions for Use for information about how to prepare and inject Alhemo®, and how to properly throw away used pens and needles. Your healthcare provider should show you or your caregiver how to use Alhemo® before you use it for the first time.

 check Alhemo® pen and attach new needle

1.

Check Alhemo® pen

2.

Attach new needle

 Prime before each dose and select dose

3.

Prime before each dose

Dial 1 marking to test flow before each dose.

4.

Select dose

 Prepare injection site and inject Alhemo®

5a.

Prepare injection site

5b.

Inject Alhemo®b,c

 Remove needle and recap pen

6.

Remove needle

7.

Recap pen

bYou can inject in the skin of your stomach area (abdomen) at least 2 inches from your belly button (navel) or your upper legs (thigh). Change (rotate) your injection site with each injection every day. Do not use the same site for each injection. Do not inject into skin that is tender, bruised, red, or hard, or in areas where there are moles, scars, or stretch marks.

 

cAfter the dose counter is at “0,” count slowly to 6 while the needle is still in your skin.

Remember to:

 Check mark icon

Rotate injection sites daily

Rotate injection sites daily

 Check mark icon

ALWAYS use a new needle for each injection

ALWAYS use a new needle for each injection

 Check mark icon

NEVER share Alhemo® pens and needles with another person, even if the needle is changed

NEVER share Alhemo® pens and needles with another person, even if the needle is changed

Alhemo® is recommended to be used with NovoFine® and NovoFine® Plus 32G 4 mm injection needles.

Available in 3 pen options to meet your individual dosing needs

Each pen contains multiple doses of Alhemo®

 Alhemo® pens with dosing information

1 gold label pen (150 mg/1.5 mL) has about 10 days of daily Alhemo® treatment:


10 days of 0.2 mg/kg daily maintenance treatment for a patient weighing 154 lb (70 kg)

Alhemo®: Effective bleed prevention in an injection pen designed with you in mind

Hemophilia B with inhibitors
Hemophilia B with inhibitors
Hemophilia A with inhibitors

Alhemo® offers innovative administrationd

Not intended to be a comparison of efficacy or safety

Alhemo® offers innovative administrationd

Not intended to be a comparison of efficacy or safety

dRead the Instructions for Use for information about how to prepare and inject Alhemo®, and how to properly throw away used pens and needles. Your healthcare provider should show you or your caregiver how to use Alhemo® before you use it for the first time.

 

eFor a patient weighing 70 kg, on Alhemo® 0.2 mg/kg, the volume to inject ranges from 0.14 mL to 0.35 mL, depending on pen size. For a patient weighing 70 kg, a single infused dose of NovoSeven® RT for a joint bleed (90 mcg/kg) is 6.3 mL. For a patient weighing 70 kg, a single infused dose of SEVENFACT® for a joint bleed (75 mcg/kg) is 5.25 mL. For a patient weighing 70 kg, a single infused dose of FEIBA® for a joint bleed (75 U/kg) is 105 mL. Qfitlia® volume to inject is 0.5 mL for a 50 mg dose, 0.2 mL for a 20 mg dose, and 0.1 mL for a 10 mg dose.

 

fAntithrombin is a protein in the blood that prevents the formation of clots.

 

gNovoSeven® RT and FEIBA® can be stored at 36 °F to 77 °F. SEVENFACT® can be stored at 36 °F to 86 °F.

NovoCare®: Support for your treatment journey

Concerned about costs and other aspects of your hemophilia with inhibitors medication? Novo Nordisk’s comprehensive patient support program can provide copay assistance, dedicated patient liaisons, interim products, and our Patient Assistance Program for eligible patients.

Discover NovoCare®

Can I speak with someone who can educate me about Alhemo®?

Connect with an RCBL
Can I speak with someone about Alhemo®
Show more Show less

Important Safety Information

What is the most important information I should know about Alhemo®?

  • It is important to follow the daily dosing schedule of Alhemo® to stay protected against bleeding. This is especially important during the first 4 weeks of treatment to make sure a correct maintenance dose is established. Use Alhemo® exactly as prescribed by your healthcare provider (HCP). Do not stop using Alhemo® without talking to your HCP. If you miss doses or stop using Alhemo®, you may no longer be protected against bleeding
  • Your HCP may prescribe bypassing agents during treatment with Alhemo®. Carefully follow your HCP’s instructions regarding when to use on-demand bypassing agents, and the recommended dose and schedule for breakthrough bleeds

Do not use Alhemo® if you are allergic to concizumab-mtci or any of the ingredients in Alhemo®.

Before using Alhemo®, tell your HCP about all of your medical conditions, including if you:

  • Have a planned surgery. Talk to your HCP about when to stop using Alhemo® and when to start it again if you have a planned surgery
  • Are pregnant, breastfeeding, or plan to become pregnant or to breastfeed. It is not known if Alhemo® may harm your unborn baby or if Alhemo® passes into your breast milk
    • Your HCP may do a pregnancy test before you start treatment with Alhemo®.
    • Females who are able to become pregnant, talk to your HCP about using effective birth control (contraception) methods during treatment with Alhemo® and for 7 weeks after ending treatment

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and supplements.

What are the possible side effects of Alhemo®?

Alhemo® may cause serious side effects, including:

  • Blood clots (thromboembolic events). Alhemo® may cause blood clots to form in blood vessels, such as in your arms, legs, heart, lung, brain, eyes, kidneys, or stomach. You may be at risk for getting blood clots if you use high or frequent doses of factor products or bypassing agents to treat breakthrough bleeds, or if you have certain conditions. Get medical help right away if you have any signs and symptoms of blood clots, including: swelling, warmth, pain, or redness of the skin; headache; trouble speaking or moving; eye pain or swelling; sudden pain in your stomach or lower back area; feeling short of breath or severe chest pain; confusion; numbness in your face; and problems with your vision
  • Allergic reactions. Alhemo® can cause allergic reactions, including redness of the skin, rash, hives, itching, and stomach-area (abdominal) pain. Stop using Alhemo® and get emergency medical help right away if you develop any signs or symptoms of a severe allergic reaction, including: itching on large areas of skin; trouble swallowing; wheezing; pale and cold skin; dizziness due to low blood pressure; redness or swelling of lips, tongue, face, or hands; shortness of breath; tightness of the chest; and fast heartbeat

The most common side effects of Alhemo® include: bruising, redness, bleeding, or itching at the site of injection, and hives. These are not all the possible side effects of Alhemo. Call your doctor for medical advice about side effects.

Please see Prescribing Information and Medication Guide for Alhemo®.

Alhemo® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

What is Alhemo®?

Alhemo® (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors.

  • It is not known if Alhemo® is safe and effective in people receiving ongoing immune tolerance induction (ITI) or in children younger than 12 years of age

What is Alhemo®?

Alhemo® (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors.

  • It is not known if Alhemo® is safe and effective in people receiving ongoing immune tolerance induction (ITI) or in children younger than 12 years of age

Show more Show less
Show more Show less

What is Alhemo®?

Alhemo® (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors.

  • It is not known if Alhemo® is safe and effective in people receiving ongoing immune tolerance induction (ITI) or in children younger than 12 years of age

What is Alhemo®?

Alhemo® (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors.

  • It is not known if Alhemo® is safe and effective in people receiving ongoing immune tolerance induction (ITI) or in children younger than 12 years of age

Important Safety Information

What is the most important information I should know about Alhemo®?

  • It is important to follow the daily dosing schedule of Alhemo® to stay protected against bleeding. This is especially important during the first 4 weeks of treatment to make sure a correct maintenance dose is established. Use Alhemo® exactly as prescribed by your healthcare provider (HCP). Do not stop using Alhemo® without talking to your HCP. If you miss doses or stop using Alhemo®, you may no longer be protected against bleeding
  • Your HCP may prescribe bypassing agents during treatment with Alhemo®. Carefully follow your HCP’s instructions regarding when to use on-demand bypassing agents, and the recommended dose and schedule for breakthrough bleeds

Do not use Alhemo® if you are allergic to concizumab-mtci or any of the ingredients in Alhemo®.

Important Safety Information

What is the most important information I should know about Alhemo®?

  • It is important to follow the daily dosing schedule of Alhemo® to stay protected against bleeding. This is especially important during the first 4 weeks of treatment to make sure a correct maintenance dose is established. Use Alhemo® exactly as prescribed by your healthcare provider (HCP). Do not stop using Alhemo® without talking to your HCP. If you miss doses or stop using Alhemo®, you may no longer be protected against bleeding
  • Your HCP may prescribe bypassing agents during treatment with Alhemo®. Carefully follow your HCP’s instructions regarding when to use on-demand bypassing agents, and the recommended dose and schedule for breakthrough bleeds

Do not use Alhemo® if you are allergic to concizumab-mtci or any of the ingredients in Alhemo®.

Before using Alhemo®, tell your HCP about all of your medical conditions, including if you:

  • Have a planned surgery. Talk to your HCP about when to stop using Alhemo® and when to start it again if you have a planned surgery
  • Are pregnant, breastfeeding, or plan to become pregnant or to breastfeed. It is not known if Alhemo® may harm your unborn baby or if Alhemo® passes into your breast milk
    • Your HCP may do a pregnancy test before you start treatment with Alhemo®.
    • Females who are able to become pregnant, talk to your HCP about using effective birth control (contraception) methods during treatment with Alhemo® and for 7 weeks after ending treatment

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and supplements.

What are the possible side effects of Alhemo®?

Alhemo® may cause serious side effects, including:

  • Blood clots (thromboembolic events). Alhemo® may cause blood clots to form in blood vessels, such as in your arms, legs, heart, lung, brain, eyes, kidneys, or stomach. You may be at risk for getting blood clots if you use high or frequent doses of factor products or bypassing agents to treat breakthrough bleeds, or if you have certain conditions. Get medical help right away if you have any signs and symptoms of blood clots, including: swelling, warmth, pain, or redness of the skin; headache; trouble speaking or moving; eye pain or swelling; sudden pain in your stomach or lower back area; feeling short of breath or severe chest pain; confusion; numbness in your face; and problems with your vision
  • Allergic reactions. Alhemo® can cause allergic reactions, including redness of the skin, rash, hives, itching, and stomach-area (abdominal) pain. Stop using Alhemo® and get emergency medical help right away if you develop any signs or symptoms of a severe allergic reaction, including: itching on large areas of skin; trouble swallowing; wheezing; pale and cold skin; dizziness due to low blood pressure; redness or swelling of lips, tongue, face, or hands; shortness of breath; tightness of the chest; and fast heartbeat

The most common side effects of Alhemo® include: bruising, redness, bleeding, or itching at the site of injection, and hives. These are not all the possible side effects of Alhemo. Call your doctor for medical advice about side effects.

Please see Prescribing Information and Medication Guide for Alhemo®.

Alhemo® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Important Safety Information

What is the most important information I should know about Alhemo®?

  • It is important to follow the daily dosing schedule of Alhemo® to stay protected against bleeding. This is especially important during the first 4 weeks of treatment to make sure a correct maintenance dose is established. Use Alhemo® exactly as prescribed by your healthcare provider (HCP). Do not stop using Alhemo® without talking to your HCP. If you miss doses or stop using Alhemo®, you may no longer be protected against bleeding
  • Your HCP may prescribe bypassing agents during treatment with Alhemo®. Carefully follow your HCP’s instructions regarding when to use on-demand bypassing agents, and the recommended dose and schedule for breakthrough bleeds

Do not use Alhemo® if you are allergic to concizumab-mtci or any of the ingredients in Alhemo®.

Before using Alhemo®, tell your HCP about all of your medical conditions, including if you:

  • Have a planned surgery. Talk to your HCP about when to stop using Alhemo® and when to start it again if you have a planned surgery
  • Are pregnant, breastfeeding, or plan to become pregnant or to breastfeed. It is not known if Alhemo® may harm your unborn baby or if Alhemo® passes into your breast milk
    • Your HCP may do a pregnancy test before you start treatment with Alhemo®.
    • Females who are able to become pregnant, talk to your HCP about using effective birth control (contraception) methods during treatment with Alhemo® and for 7 weeks after ending treatment

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and supplements.

What are the possible side effects of Alhemo®?

Alhemo® may cause serious side effects, including:

  • Blood clots (thromboembolic events). Alhemo® may cause blood clots to form in blood vessels, such as in your arms, legs, heart, lung, brain, eyes, kidneys, or stomach. You may be at risk for getting blood clots if you use high or frequent doses of factor products or bypassing agents to treat breakthrough bleeds, or if you have certain conditions. Get medical help right away if you have any signs and symptoms of blood clots, including: swelling, warmth, pain, or redness of the skin; headache; trouble speaking or moving; eye pain or swelling; sudden pain in your stomach or lower back area; feeling short of breath or severe chest pain; confusion; numbness in your face; and problems with your vision
  • Allergic reactions. Alhemo® can cause allergic reactions, including redness of the skin, rash, hives, itching, and stomach-area (abdominal) pain. Stop using Alhemo® and get emergency medical help right away if you develop any signs or symptoms of a severe allergic reaction, including: itching on large areas of skin; trouble swallowing; wheezing; pale and cold skin; dizziness due to low blood pressure; redness or swelling of lips, tongue, face, or hands; shortness of breath; tightness of the chest; and fast heartbeat

The most common side effects of Alhemo® include: bruising, redness, bleeding, or itching at the site of injection, and hives. These are not all the possible side effects of Alhemo. Call your doctor for medical advice about side effects.

Please see Prescribing Information and Medication Guide for Alhemo®.

Alhemo® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

What is Alhemo®?

Alhemo® (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors.

  • It is not known if Alhemo® is safe and effective in people receiving ongoing immune tolerance induction (ITI) or in children younger than 12 years of age

What is Alhemo®?

Alhemo® (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors.

  • It is not known if Alhemo® is safe and effective in people receiving ongoing immune tolerance induction (ITI) or in children younger than 12 years of age

Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.
Alhemo®, NovoCare®, and NovoSeven® RT are registered trademarks of Novo Nordisk Health Care AG.
NovoFine® is a registered trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.

© 2025 Novo Nordisk All rights reserved. US25AHM00125 June 2025

Please see Prescribing Information, Medication Guide, and Instructions for Use.

Please see Prescribing Information, Medication Guide, and Instructions for Use.

You are about to leave alhemo.com, a Novo Nordisk website

Click “Continue” to leave this site and come back to visit us another time. Click “Return to site” to stay and learn more about Alhemo.

Continue

You are about to leave alhemo.com, a Novo Nordisk website

Click “Continue” to leave this website. Novo Nordisk is not responsible for content that follows. Please come back to visit us another time.

Click “Return to site” to stay and learn more about Alhemo.

Continue
Access Resources